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Summal'y 
Draining lymph node cells (LNC) from mice immunized with hen egg white lysozyme (HEL) 
display at their surface antigen-MHC complexes able to stimulate, in the absence of any further 
antigen addition, HEL peptide-specific, dass II-restricted T cell hybridomas. Chloroquine addition 
to these LNC cultures fails to inhibit antigen presentation, indicating that antigenic complexes 
of class II molecules and HEL peptides are formed in vivo. MHC class II restriction of antigen 
presentation by LNC from HEL-primed mice was verified by the use of anti-class II monoclonal 
antibodies.  Coinjection of HEL and the I-Ak-binding  peptide HEL 112-129 in mice of H-2  k 
haplotype inhibits the ability of LNC to stimulate I-Ak-restricted,  HEL 46-61-specific  T  cell 
hybridomas. Similar results are obtained in mice coinjected with the HEL peptides 46-61 and 
112-129. Inhibition of T hybridoma activation can also be observed using as antigen-presenting 
cells irradiated,  T cell-depleted LNC from mice coinjected with HEL 46-61 and HEL 112-129, 
ruling out the possible role of either specific or nonspecific suppressor T cells. Inhibition of T 
cell proliferation is associated with MHC-specific inhibition of antigen presentation and with 
occupancy by the competitor of class II binding sites, as measured by activation of peptide-specific 
T cell hybridomas. These results demonstrate that administration of MHC class II binding peptide 
competitors selectively inhibits antigen presentation to class II-restricted T  cells, indicating 
competitive blockade of class II molecules in vivo. 
p eptides bound to class II MHC molecules on the surface 
of APC are the ligand for specific TCRs of CD4 + T 
cells (1). In the past few years, peptide-MHC interactions 
have been characterized  in detail by structural, biochemical, 
and functional analysis (reviewed in reference 2), clarifying 
at the molecular level several aspects of the binding of anti- 
genic peptides to class I and class II MHC molecules. Since 
each MHC class II molecule binds many different peptides, 
peptides of rather different sequences can compete for an- 
tigen presentation by a given class II molecule to T  lym- 
phocytes. 
Peptide competition for  antigen presentation has  been 
demonstrated in vitro, by showing that peptides binding to 
the same class II molecule can compete with each other for 
presentation to T  cells  (3-6).  Several studies have clearly 
demonstrated a direct correlation between the capacity of a 
peptide to bind to purified class II molecules and its ability 
to compete for presentation with antigenic peptides binding 
to the same class II molecule (7, 8). 
It has been postulated that peptide competition for the 
MHC class II binding site may occur also in vivo (9). This 
was first implied by the observation that self-peptides could 
compete with non-self antigens for T cell priming (10). In 
addition, in vivo competition between different peptides de- 
rived by processing of the same protein antigen has been shown 
to profoundly influence the immunodominance  of T cell de- 
terminants (11). 
More recently,  several groups (12-15) have reported that 
this approach could be applied to prevention of experimental 
autoimmune diseases, such as experimental autoimmune en- 
cephalomyelitis (EAE) 1 or autoimmune carditis.  However, 
in most of the EAE studies (12, 13), disease induction by 
encephalitogenic peptides was prevented by coinjection of a 
close analogue of the encephalitogenic peptides, raising the 
1Abbreviations used in  this paper: EAE, experimental autoimmune 
encephalomyelitis;  HEL, hen egg-white  lysozyme;  LNC, lymph  node  cells. 
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mechanisms in disease prevention (16). Indeed, this was later 
demonstrated to be the case (17). EAE has also been prevented 
by injection of a competitor peptide nonhomologous to the 
encephalitogenic peptide, but since the competitor peptide 
was itself immunogenic, clonal dominance in the T  cell re- 
sponse to the competitor could not be excluded as a possible 
cause  of EAE prevention (14). 
To clarify these issues and to examine more directly the 
mechanism inhibiting in vivo T cell activation by adminis- 
tration of class II-binding peptide competitors, we first es- 
tablished an ex vivo system to detect complexes between an- 
tigenic peptides and class II molecules generated in vivo and 
expressed on the surface of lymph node cells (LNC). Then, 
we coinjected antigenic and competitor peptides of different 
sequences that bind to the same class II molecule, and exam- 
ined the in vivo formation of antigenic peptide-MHC com- 
plexes. Results in the present paper demonstrate that, under 
these conditions, administration of class II-binding peptide 
competitors specifically inhibits in vivo the capacity of LNC 
to present antigen to MHC class II-restricted T  cells. 
Materials  and Methods 
Mice.  8-wk-old  C3H, B10.D2, and DBA/2 female mice, iso- 
lator reared and virus free, were obtained from Iffa Credo (E Ar- 
besle, France). 
Antigens.  HEL (recrystallized  three times) was obtained from 
Sigma Chemical Co. (St. Louis, MO). Peptides were synthesized 
by the solid-phase  method on PAM-polystyrene  support using side- 
chain protection, coupling procedures, and an automated apparatus 
(430A; Applied Biosystems, Inc., Foster City, CA), as described 
(10). The peptides were purified by preparative HPLC on a C18 
reverse-phase column and showed correct amino acid ratios upon 
hydrolysis  in 6 N HC1 and the expected molecular ions in fast atom 
bombardment mass spectrometry. Sequences were confirmed by 
gas-phase microsequencing. 
T Cell Proliferation.  Mice  were immunized subcutaneously  into 
the hind footpads with 1-14 nmol antigen (HEL or HEL peptides) 
emulsified  in CFA containing H37Ra mycobacteria  (Difco Labora- 
tories, Detroit, MI). 8 d later, popliteal lymph node cells were cul- 
tured  (4  x  105/well) in microtiter plates (Costar, Cambridge, 
MA) in HL-1 medium (Ventrex Laboratories,  Portland, ME). Cul- 
tures were set up in triplicate from pooled LNC of  individual mice. 
Cultures were incubated for 3 d in a humidified atmosphere of 5% 
CO2 in air and pulsed 10 h before harvesting with 1 gCi [3H]TdR 
(40 Ci/mmol; The Radiochemical Center, Amersham, UK). In- 
corporation of [3H]TdR was measured by liquid scintillation spec- 
trometry. 
T Cell Hybn'domas.  T cell hybridomas  were established  by poly- 
ethylene glycol-induced fusion of LNC with the thymoma line 
BW5147, as previously  described (8, 11). LNC were obtained from 
mice immunized with HEbCFA and restimulated in vitro with 
7 gM HEL before cell fusion. Cultures containing 5 x  104 T hy- 
bridoma cells and 2.5  x  104 LK-35.2 (H-2  k/a) cells (obtained from 
the American Type Culture Collection, Rockville, MD) were set 
up with or without antigen in 0.2 ml of culture medium. Culture 
medium was RPMI 1640 (Gibco, Basel, Switzerland)  supplemented 
with 2 mM r-glutamine,  50 mM 2-ME, 50 gg/ml  gentamicin 
(Sigma Chemical Co.) and 10% FCS (Gibco). After 24 h of cul- 
ture, 50-/~1 aliquots of supernatant were transferred to microcul- 
ture wells containing l& CTLL cells and, after an additional 24-h 
incubation, the presence of T cell growth factors (TCGF), mainly 
Ib2, was assessed by [3H]TdR incorporation during the last 4 h 
of culture. Hybridoma cells reactive to HEL peptides were cloned 
by limiting dilution at 0.3 cells/well. The MHC class II molecule 
involved in antigen recognition by individual T cell hybridomas 
obtained from C3H mice was determined by comparing the TCGF 
production obtained in the presence of  irradiated (2,400 tad) spleen 
cells from C3H (expressing I-A  k and I-E  k molecules) and B10.A(4K) 
(expressing only I-A  k molecules) mice. The I-Ea-restricted (8) and 
the I-Ek-restricted (18) T cell hybridomas have been previously  de- 
scribed. The 3A9 T hybridoma (19) was a kind gift of Dr. Paul 
Allen (Washington University, St. Louis, MO). The T cell hybrid- 
omas used in the present study are listed in Table 1. 
T Ceil Activation Assays.  HEL-specific  T cell hybridomas (5  x 
104 cells/well) were cultured in duplicate or triplicate with a dose 
range (0.1-1  x  106) of irradiated (2,400 tad) popliteal LNC from 
mice primed into the hind footpads 8 d before with HEL or HEL 
peptides (1-14 nmol/mouse) emulsified  in CFA. Culture conditions 
and assessment of Ib2 production were as described above. The 
MHC class II molecule involved in antigen presentation by LNC 
was determined by inhibition of T cell activation with the mAbs 
12-2.16, anti-I-A  fJ'k  ...... (20), and 14-4-4S, anti-I-E (21). 
Chloroquine Treatment.  Irradiated  LNC were incubated in cul- 
ture  medium containing the lysosomotropic agent chloroquine 
(Sigma Chemical Co.) for 30 min at 37~  before adding antigen. 
After a 4-h incubation with chloroquine and antigen, the LNC 
were washed three times with RPMI, and their capacity to acti- 
vate T cell hybridomas was tested as described above. 
Anti.Thy-1 Cytotoxic Treatment.  LNC (6  x  106/ml) were in- 
cubated with 1.5 gg/ml of  purified anti-Thy-l.2  mAb (Becton  Dick- 
inson & Co., Mountain View, CA) for 1 h at 4~  Cells were then 
washed once, resuspended  in low-tox rabbit complement (Cedarlane 
Laboratories, London, Canada) at a final  dilution of 1:15, incubated 
45 min at 37~  and then washed three times. T cell depletion 
was assessed  by lack of responsiveness to Con A (Sigma Chemical 
Co.) and by cytofluorimetric analysis  with biotinylated anti-CD4 
mAb (Becton Dickinson & Co.). 
Results 
Activation of Class II-restricted, HEL Peptide-specific T Cell 
Hybridomas by Irradiated LNC from HEL.primed Mice.  The 
basic experimental design of the present study relied on the 
hypothesis that draining LNC from HEl.-primed mice would 
include APC expressing on their surface immunologically  de- 
tectable complexes of naturally processed HEL peptides bound 
to class II MHC molecules. To test this hypothesis, C3H and 
DBA/2 mice were immunized with HEI.-CFA. 8 d later, 
draining LNC were irradiated and incubated, in the absence 
of added antigen, with the T  cell hybridoma 3A9, recog- 
nizing the  HEL peptide 46-61  bound to  I-A  k molecules 
(19), or with the T cell hybridoma 1Hll.3, recognizing the 
HEL  peptide  108-116 bound  to  I-E  d molecules  (8,  22). 
Results in Fig.  1 demonstrate that LNC from HEL-primed 
C3H mice induce II.-2 production by 3A9 but not by 1Hll.3 
T  cells. Conversely,  LNC from HEL-primed DBA/2 mice 
induce IL-2 production by 1Hll.3 but not by 3A9 T  cells. 
Activation of T  cell hybridomas is maximal using as APC 
0.5-1  x  106 LNC/well from HEL-primed mice. LNC from 
CFA-primed mice of either strain fail to induce activation 
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Responsiveness 
HEL peptide  Amino acid 
Denomination  specificity  sequence  Restriction  HEL  peptide  Reference 
~M 
1c5.1  46-61  NTDGSTDYGILQINSR  A  k  0.3  0.1  This paper 
3A9  46-61  A k  0.02  0.04  19 
2D4.1  112-129  RNRCKGTDVQAWIRGARL  A  k  0.3  0.03  This paper 
1Hll.3  108-116  WVAWRNRCK  E  a  0.5  0.3  8 
2G7.1  1-18  KVFGRCELAAAMKRHGLD  E  k  0.3  0.3  18 
The responsiveness of T cell hybridomas was estimated by titrating antigen on LK-35.2 cells as APC. Values (mean of three to four experiments) 
represent  the amount of HEL  or peptide inducing 50% of the maximal response. HEL peptide  sequences are indicated by the single-letter code. 
of HEbspecific T cell hybridomas. Similarly, irradiated LNC 
from HEL-primed mice, cultured alone, fail to produce IL-2 
(not shown). A direct relationship  exists between the dose 
of antigen injected and the degree of T cell hybridoma acti- 
vation induced by LNC from primed mice. This is exemplified 
in Fig. 2 by the response of hybridoma 1C5.1, recognizing 
the  HEL  peptide  46-61  together  with  I-A k  molecules. 
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Figure  1.  Activation of MHC class II-restricted T cell hybridomas by 
irradiated lymph node cells from HEL-primed mice. C3H, H-2  k (A and 
B) or DBA/2,  H-2  d (C and D)  mice were  immunized into the hind 
footpads with CFA alone (A and C) or with 7 nmol/mouse HEL-CFA 
(B and D). 8 d later popliteal LNC from individual mice were irradiated 
(2,400  tad)  and  the  indicated  cell  numbers cultured with  5  x  104 
cells/well of T hybridomas  3A9 (A, I-Ak/HEL 46-61)  or 1Hll.3 (O, 
I-Ed/HEL  108-116). After  24 h,  antigen-specific T  cell growth factor 
production was determined by adding 50-/~I  aliquots of culture superna- 
tant  to  104  CTLL  cells for  an  additional  24  h.  [3H]Thymidine  (1 
#Ci/well) was added during the last 5 h of culture.  Data are presented 
as mean thymidine incorporation (cpm) from triplicate  cultures. Background 
proliferation  of CTLL cells was 600 cpm. 
Draining LNC from C3H mice primed with different doses 
of HEL (Fig. 2, A-C) or of HEL peptide 46-61 (Fig. 2, D-F) 
induce a similar,  dose-dependent, activation of hybridoma 
1C5.1. 
These results demonstrate that lymph node cells from HEL- 
primed mice contain APC expressing complexes of HEL pep- 
tides and class II MHC molecules, as detected by appropriate 
T  cell hybridomas.  The antigen-presenting activity can be 
detected in LNC 6-12 d after immunization, but it is max- 
imal after 8 d (not shown). 
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Figure 2.  Direct relationship between the dose of antigen injected and 
the degree of T cell hybridoma activation.  C3H mice were immunized 
with I nmol (.4), 3 nmol (B), or 10 nmol/mouse (C) HEL in CFA, or 
with I nmol (D), 3 nmol. (E), or 10 nmol/mouse (F) HEL peptide 46-61 
in CFA. Culture conditions were as in Fig. 1, except that the read-out 
T  cell hybridoma  was 1C5.1 (I-Ak/HEL 46-61).  Data from individual 
mice are presented as in Fig.  1. 
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II Molecules Are Formed In Vivc~  To assess whether antigenic 
complexes are formed in vivo, rather than by carry-over of 
HEL in vitro,  we incubated  LNC from HEL-primed mice 
with the lysosomotropic  agent chloroquine before addition 
of the T  cell hybridoma 1C5.1. Results  in Fig. 3 demon- 
strate that chloroquine fails to interfere with antigen presen- 
tation by LNC from HEbprimed mice, whereas it prevents 
presentation of HEL but not of the HEL peptide 46-61 by 
LNC from CFA-primed mice. These results indicate the pres- 
ence of preformed complexes between antigenic HEL pep- 
tides and class II molecules in LNC from HEL-primed mice. 
To  confirm the MHC  class II  restriction of LNC  an- 
tigen-presenting activity, anti-I-A and anti-I-E mAbs were 
added to cultures of LNC from HEbprimed mice and T cell 
hybridomas.  Results in Fig. 4 A demonstrate that anti-I-A, 
but not anti-I-E, antibodies abrogate antigen presentation to 
the I-ALrestricted  hybridoma IC5.1.  Conversely, anti-I-E, 
but not anti-I-A, antibodies completely inhibit activation of 
the I-Ed-restricted hybridoma 1Hll.3  (Fig. 4 B). 
MHC-specific Inhibition of I-Ak-restricted T Cell Proliferation 
by Administration of I-Ak-binding Peptide Competitors.  The 
mouse lysozyme (ML) peptide 46-62 binds strongly to I-A  k 
molecules, but it fails to bind to I-E  k or I-E  d molecules (5, 
10, 23). Previous experiments have demonstrated that injec- 
tion of this peptide competitor inhibits in vivo T cell activa- 
tion by I-ALbinding antigenic peptides (10). The exquisite 
specificity of this inhibitory activity is illustrated in Fig. 5. 
The T cell response induced by HEL in C3H mice can be 
recalled by several dominant HEL peptides (11, 24), among 
them 1-18 and 112-129 (Fig. 5 A). Since the response to HEL 
1-18 is I-E  k restricted and the response to 112-129 I-A  k re- 
stricted (11), we asked whether coinjection of HEL and ML 
46-62 in C3H mice would inhibit only I-ALrestricted T cell 
induction. Results in Fig. 5 B demonstrate that injection of 
ML 46-62 completely inhibits  T cell proliferation  to HEL 
112-129, but, in the same lymph node cell population, there 
is no inhibition of the T cell response to HEL 1-18. ML 46-62 
is nonimmunogenic in mice and therefore the observed inhi- 
bition cannot be ascribed to induction of clonal dominance 
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Figure 3.  Antigenic complexes 
between HEbderived peptides and 
class II molecules  are formed in vivo. 
Irradiated  LNC  from C3H  mice 
primed with 14 nmol/mouse HEL 
in CFA (106 ceUs/well, O) or with 
CFA only (2.5  ￿  10  s cells/well, [] 
and t)  were incubated  with the 
indicated  concentrations  of  the 
lysosomotropic agent chloroquine 
30 min  before the addition of 2 #M 
HEL (O) or 2 #M HEL 46-61 ([]). 
After a 4-h incubation  at 37~  the 
LNC were washed, the T cell hy- 
bridoma 1C5.1 was added, and the 
experiment continued as in Fig. 1. Control responses were 165,482 (O), 
177,128 (O), and 321,537 ([]) cpm. Background proliferation of CTLL 
cells was 566 cpm. 
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Figure 4.  The antigen-presenting  activity of LNC from HEL-primed 
mice is MHC class II restricted. Irradiated LNC from C3H (.4) or B10.D2, 
H-2  d (B) mice primed with 14 nmol/mouse HEL in CFA were cultured 
(0.5  x  106 cells/well) in medium containing the indicated dilutions of 
mAb 10-2.16, anti-I-A (O), or 14-4-4S, anti-l-E (Q), and the T cell hy- 
bridomas  1C5.1 (Ak/HEL 46-61, A) or 1Hl1.13 (Ea/HEL  108-116, B). 
Ib2 production was measured as in Fig. 1. Control responses were 79,582 
(A) and 15,208 (B) cpm. Background proliferation of CTLL cells was 354 
cpm. 
by the competitor  peptide. However, in the experiment il- 
lustrated in Fig. 5, mice were injected with HEL and inhibi- 
tion of T cell proliferation to 112-129 could have been medi- 
ated, across an antigen bridge, by suppressor T cells induced 
by ML 46-62 (25). To eliminate this possibility, we used as 
antigen the HEL peptide 112-129 and as competitor the se- 
quence 46-61 either of hen or mouse origin. Results in Fig. 
6 A demonstrate that either HEL 46-61 or ML 46-62, coin- 
jected  with  HEL  112-129,  inhibit  T  cell  proliferation to 
112-129.  The degree of inhibition  is unrelated to the im- 
munogenicity of the inhibitory peptide, since a similar inhi- 
bition is exerted by the immunogenic peptide HEL 46-61 
and the nonimmunogenic ML 46-62.  The inhibition  of T 
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Figure 5.  MHC-specific inhibition  of T cell priming. C3H mice were 
immunized subcutaneously into the hind footpads with 14 nmol/mouse 
HEL in CFA (A) or with a mixture of 14 nmol HEL and 140 nmol ML 
46-62/mouse (/3). 8 d later the popliteal LNC from four mice were pooled 
and restimulated in vitro with the indicated concentrations  of the HEL 
peptides 1-18 (O) or 112-129 (0). After 3 d of culture, 1/~Ci [3H]thymi- 
dine was added and the calls harvested 10 h later. Data are presented as 
mean _+ SEM of cpm from triplicate cultures. Background (no antigen) 
cpm were 2,234 (A) and 1,244 (B). 
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Figure 6.  Reciprocal inhibition of T cell priming by injection of pep- 
tide competitors  non homologous to the antigenic peptides. C3H mice 
(.4) were immunized with 14 nmol/mouse HEL 112-129 alone (O) or 
mixed either with 100 nmol ML 46-62 (/'7),  HEL 46-61  (0), or HEL 
64-77  (,).  Alternatively  (B), C3H  mice  were  immunized with  1 
nmol/mouse HEL 46-61 alone (O) or mixed either with 100 nmo1112-129 
(0) or 100 nmo164-77 ([]), 8 d later popliteal LNC from four mice were 
pooled and restimulated in vitro with different concentrations of" the indi- 
cated peptides. Results are expressed as in Fig. 5. Background values ranged 
from 2,799 to 10,236 cpm. The amino acid sequence, in the single-letter 
code, of the HEL peptide 64-77 is CNDGRTPGSRNLCN,  and that of 
ML 46-62 DRGDQSTDYGIFQINSR. 
cell activation  in vivo depends on the molar ratio between 
antigenic and competitor peptide, since HEL 46-61 can also 
function as antigen and HEL  112-129 as competitor  (Fig. 
6 B). In either case, no inhibition of T cell activation is ob- 
served by coinjection of HEL 64-77,  which does not bind 
to I-A k (11). 
MHC-specific Inhibition of I-Ak-restricted  Antigen Presentation 
by Administration of I-Ak-binding Peptide Competitors.  Having 
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Figure 7.  MHC-specific inhibition of antigen presentation. C3H mice 
were immunized with 1 nmol HEL/mouse mixed either with 100 nmol 
HEL  64-77  (,4)  or  100  nmol  112-129 (B),  or  with  3  nmol  HEL 
46-61/mouse mixed either with 100 nmol HEL 64-77 (C) or 100 nmol 
112-129 (D).  Irradiated  LNC from individual mice were cultured with 
the T cell hybridoma  1C5.1 (Ak/HEL 46-61),  and I1-2 production  was 
measured as in Fig.  1. Bars represent  II:2 production  induced by 2.5  x 
10  s LNC/well from the same individual mice and 2 #M HEL in 1C5.1 
cells. Background proliferation of CTLL cells was 410 (A and B) and 254 
(C and D) cpm. 
established  that  detectable  antigenic complexes are formed 
in vivo between class II MHC molecules and peptides  de- 
rived from HEL processing,  we examined the effect of ad- 
ministering a class II-binding peptide competitor on the in 
vivo formation of antigenic complexes.  C3H mice were im- 
munized with HEL and 64-77 in CFA, or with an emulsion 
containing HEL  and  112-129.  Alternatively,  HEL  46-61 
replaced HEL as antigen. 8 d later, irradiated LNC were tested 
for their capacity  to activate the I-A~-restricted hybridoma 
1C5.1, specific for HEL 46-61. Results in Fig. 7 demonstrate 
that, in either case, coinjection of the I-Ak-binding peptide 
competitor inhibits profoundly the I-Ak-restricted antigen- 
presenting activity.  The specificity  of the inhibitory effect 
is also indicated by the unimpaired ability of LN APC from 
competitor-injected  mice to process and present in vitro ex- 
ogenous HEL. This demonstrates  that APC from mice in- 
jected with a class II-blocking peptide able to prevent the 
formation of antigenic complexes in vivo can present exoge- 
nous antigens added in vitro, presumably due to newly syn- 
thetized MHC class II molecules. 
To correlate the inhibition of T cell proliferation with the 
inhibition of antigen presentation,  C3H mice were injected 
with HEL alone, or mixed with either HEL 64-77 or 112-129. 
8 d later, antigen presentation  to the 46-61-specific T  cell 
hybridoma 1C5.1 and T  cell proliferation  to the HEL pep- 
tide 46-61 was simultaneously tested in the same LNC popu- 
lations.  Results in Fig.  8 demonstrate  that injection of the 
I-Ak-binding  peptide  HEL  112-129  inhibits  equally  well 
I-Ak-restricted antigen presentation  and T cell proliferation 
by LNC. This indicates that MHC blockade is equally effec- 
tive in inhibiting antigen presentation  to T cell hybridomas 
as well as to bulk T  cells. 
Inhibition of Antigen-presenting Activity Does Not Require T 
Cells.  To exclude the possibility that suppressor T cells in- 
duced by HEL 112-129 in the LNC population could inhibit 
activation of T cell hybridomas,  T cell-depleted LNC from 
HEL 46-61-primed C3H mice, coinjected with HEL 112-129 
or with HEL 64-77,  were used as APC. Results in Fig.  9 
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Figure 8.  Correlation between inhibition of antigen presentation and 
inhibition of T cell priming. C3H mice were immunized with 3 nmol 
HEL/mouse alone (O) or mixed either with 100 nmol HEL 64-77 (O) 
or 100 nmol 112-129 (A). 8 d later, LNC from four mice were pooled, 
and either irradiated and cultured with the T cell hybridoma 1C5.1 (A) 
or restimulated in vitro with the indicated concentrations of HEL 46-61 
(B). Results  in A  and B are expressed as in Figs.  1 and 5, respectively. 
1349  Gu6ry et al. cpm x  10 "3 
0 
no treatment  i 
C' only 
antl-Thy.1  + C'  I 
10  20  30  40 
F-, 
50  100  150  200  250 
,  i  ,  t  ,  i  ,  i  ,  i 
I  I  I  I"' 
APC: L.NC  106/~ell  /dr  LNC 25 X 104 h,~ll + HEL 2 ~M 
Figure 9.  Inhibition of antigen-presenting  activity does not require T 
cells. C3H mice were immunized with 1 nmol HEL 46-61/mouse mixed 
either with 100 nmol HEL 64-77 ([]) or 100 nmol 112-129 (m).  8 d 
later, LNC from four mice were pooled,  treated  with anti-Thy-1 mAb 
plus C', irradiated,  and cultured with the T cell hybridoma  1C5.1. Cul- 
tures were set up with 106 LNC/weU (left) or with 2.5  x  10  s LNC/well 
and 2 ~tM HEL (right), and the experiment  continued as in Fig. 1. Data 
are shown as mean  •  SEM cpm from triplicate  cultures.  Background 
proliferation  of CTLL  cells was 332 cpm. 
demonstrate  that  the  antigen-presenting  capacity  of  T 
cell-depleted LNC from 46-61-primed mice is not impaired, 
indicating that antigen presentation is not mediated by T 
cells. A similar inhibition of T hybridoma activation is ob- 
served in untreated or T cell-depleted LNC from mice coin- 
jeered with 112-129, indicating that inhibition ofT hybridoma 
activation does not depend on lymph node T  cells. Com- 
parable results are obtained using HEL as antigen (not shown). 
T cell depletion was complete, as assessed by Con A respon- 
siveness and cytoftuorimetric analysis, with anti-CD4 mAb 
(data not shown). Untreated or T cell-depleted LNC from 
control or competitor-injected mice could present equally well 
in vitro exogenous HEL to the T cell hybridoma 1C5.1. There- 
fore, these results rule out inhibition of T hybridoma activa- 
tion by suppressor T  cells. 
Detection of Competitor/I-A k Complexes Correlates with In- 
hibition  of I-Ak-restricted Antigen  Presentation.  Next,  we 
wished to demonstrate that inhibition of antigen presenta- 
tion is associated with the presence of the competitor pep- 
tide in the binding site of class II molecules. LNC from C3H 
mice, injected with HEL 46-61 alone or coinjected with ei- 
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Detection of competitor/I-A  k complexes correlates with in- 
hibition  of I-Ak-restricted  antigen  presentation.  C3H  mice were im- 
munized with 3 nmol HEL 46-61/mouse (O) alone or mixed either with 
100 nmol HEL 1-18 (0) or with 100 nmol HEL 112-129 (A). 8 d later, 
LNC from four mice were pooled, treated with anti-Thy-1 mAb plus C', 
irradiated, and then cultured with the T cell hybridomas 1C5.1 (,4), 2G7.1 
(B), or 21)4.1 (C). Results are expressed as in Fig. 1. Background prolifer- 
ation of CTLL cells was 230 cpm. 
ther the I-Ek-binding peptide 1-18 or with 112-129, were 
used to activate the specific T cell hybridomas. As expected, 
a strong decrease in the I-Ak-restricted antigen-presenting ac- 
tivity of LNC was only observed in mice injected with the 
I-Ak-binding  competitor HEL  112-129,  whereas no effect 
was induced by injection of the I-Ek-binding peptide HEL 
1-18 (Fig. 10 A). Both peptides are bound to the appropriate 
dass II molecules, as detected by activation of specific T cell 
hybridomas (Fig.  10, B and C). These results demonstrate 
that inhibition of the I-Ak-restricted antigen presentation by 
LNC from competitor-injected mice correlates with the pres- 
ence of the competitor peptide in the binding site of I-A  ~ 
molecules. 
Discussion 
In vivo administration of class II-binding competitor pep- 
tides can selectively inhibit the activation of T cells induced 
by antigenic peptides binding to the same class II molecule 
(10, 14, 23). Since the inhibition of T cell priming is specific 
for the class II molecule  binding the competitor peptide, and 
it does not depend on homology between competitor and 
antigenic peptides, it was inferred, although not directly 
proven, that the underlying in vivo mechanism was inhibi- 
tion of antigen presentation by competitive binding to the 
class II molecule restricting the T cell response. Data in the 
present paper now provide evidence for this mechanism. 
Inhibition of T cell activation by injection of class II-binding 
peptides could have several possible explanations,  apart from 
competition for antigen presentation. If the inhibitor pep- 
tide is structurally closely related  to the antigenic peptide, 
antigen-specific rather than MHC-specific mechanisms may 
be involved. These include induction oft cell tolerance (26), 
induction of suppressor T cells (27), or production by T cells 
of different lymphokines (28). If inhibitory and antigenic pep- 
tides are nonhomologous, but the inhibitory peptide is im- 
munogenic, inhibition of the T cell response to antigen could 
result  from clonal dominance induced by  the  inhibitory 
peptide. 
Our previous experiments have utilized as inhibitor a nonim- 
munogenic class II-binding peptide nonhomologous to the 
antigen, suggesting MHC blockade as the cause for inhibi- 
tion of T cell activation (10, 23). Although, in this case, the 
mechanism responsible for inhibition of T cell priming ap- 
pears to be MHC blockade,  it remains to be seen whether 
this applies to all situations in which T  cell activation has 
been prevented by injection of class II-binding peptides, and 
particularly in the case of competitors sharing extensive se- 
quence homology with the antigenic peptide. In fact, in the 
latter situation, the inhibition of T cell activation could be 
easily accounted for by stimulation of suppressor T cells or 
by induction of T  cell tolerance. 
In mice of H-2  u haplotype, the acetylated NH2-terminal 
peptide (amino acid residues 1-9) of myelin basic protein is 
able to induce encephalitogenic T cells (29). Using this ex- 
perimental model, several  authors have demonstrated that coin- 
jection of competitor and encephalitogenic peptides can pre- 
vent the clinical development of EAE. Disease prevention was 
1350  In Vivo Blockade of Major Histocompatibility Complex Class II Molecules related to inhibition of encephalitogenic peptide binding to 
I-A  u molecules (12, 13), with the consequent failure to acti- 
vate encephalitogenic T cells. The evidence for this mecha- 
nism was based on the observation that peptides able to pre- 
vent  EAE  induction  were  binding  to  I-A  u better  than 
encephalitogenic peptides, both in assays using purified class 
II molecules (12) and in competition for antigen presenta- 
tion in vitro (13). However, since inhibitor and encephalito- 
genic peptides were highly homologous, induction of T cell 
tolerance or of suppressor T cells able to prevent disease in- 
duction could not be excluded (16, 17). 
EAE can also be induced in H-2 s mice by a peptide de- 
rived from the routine proteolipid protein (PLP 139-151), 
and coadministration of this encephalitogenic peptide together 
with an unrelated peptide binding to I-A  S  can prevent EAE 
induction (14). Since in this study encephalitogenic and com- 
petitor peptides did not share sequence homology, in this 
case, induction of T cell anergy or suppression by the com- 
petitor peptide does not appear to be the mechanism of dis- 
ease prevention, and indeed this is most likely accounted for 
by MHC blockade.  However, the inhibitory peptides used 
were themselves immunogenic, leaving open the possibility 
for a mechanism of clonal dominance in preventing induc- 
tion of encephalitogenic T  cells. 
To obtain evidence for MHC blockade in vivo, we first 
established an ex vivo experimental model to detect complexes 
of naturally processed antigenic peptides generated in vivo 
and expressed by MHC class II molecules on the surface of 
APC. This was accomplished by immunizing mice with HEL 
in CFA and assessing the expression of antigenic complexes 
in LNC draining the injection site by their ability to activate 
HEL peptide-specific, class II-restricted T cell hybridomas. 
Only T hybridomas responding in vitro to low antigen con- 
centrations could be activated by in vivo formed antigenic 
complexes. Activation ofT cell hybridomas like 1Hll.3 only 
requires about 50 antigenic complexes (30), suggesting that 
in vivo processing of HEL may give rise to a relatively low 
number of complexes between antigenic HEL peptides and 
class II molecules. 
Injection of I-Ak-binding peptides together with antigen 
in mice of H-2  k haplotype prevents the formation in vivo 
of antigen-I-A  ~ complexes, as assessed by activation of HEL- 
specific T cell hybridomas. Inhibition of T hybridoma acti- 
vation is observed using as APC irradiated,  T cell-depleted 
LNC from mice coinjected with antigenic and competitor 
peptides, ruling out a possible  involvement of specific or 
nonspecific suppressor T cells in preventing T cell activation. 
Since, in the experiments described  here,  the I-Ak-binding 
peptides used as competitors were always nonhomologous 
to the antigenic peptides, tolerance or T cell anergy as pos- 
sible mechanisms inhibiting T cell activation are also excluded. 
Besides excluding possible alternative mechanisms, results 
in this paper directly support MHC blockade as the mecha- 
nism preventing T cell activation in mice injected with a class 
II-binding peptide competitor. In mice coinjected with HEL 
46-61 and a molar excess of HEL 112-129, both binding to 
I-A  k molecules, competitive inhibition takes place in vivo be- 
tween these two peptides for the formation of peptide/I-A  k 
complexes. Under these conditions, inhibition of class II-re- 
stricted T cell induction by administration of MHC class II 
binding peptide competitors is associated with in vivo inhi- 
bition of antigen presentation and with occupancy by the 
competitor of class II binding sites. It is important to note 
that in vivo MHC blockade is equally effective in inhibiting 
antigen presentation to T cell hybridomas and to bulk T cells, 
indicating the relevance  of this immunosuppressive mechanism. 
In conclusion, we have demonstrated that injection of a 
class II-binding peptide competitor can selectively impair an- 
tigen presentation to class II-restricted T  cells. This effect 
appears to be due to MHC blockade, modulating T cell acti- 
vation by preventing binding of antigenic peptides to class 
II molecules. It is hoped that this approach could be applicable 
to  human systems  to  evaluate  induction of selective  im- 
munosuppression in HLA-associated  autoimmune diseases 
(31, 32). 
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